References | Participants (design) | Intensity | Intervention | Technology | Achievements |
---|---|---|---|---|---|
Chiu et al. [6] | 62 CP (AB) | 6Â ses | VR vs CONV | Commercially available | No effects |
Hammond et al. [7] | 28 DCD (AB) | 12Â ses | VR vs CONV | Commercially available | No effects |
Zoccolillo et al. [8] | 22 CP (AB) | 16 ses | VR vs CONV | Commercially available | Therapy effects |
Shin et al. [9] | 16 CP (AB) | 16 ses | VR vs CONV | Commercially available | Period effect |
Gilleaux et al. [10] | 16 CP (AB) | 40Â ses | VR + PT + OT vs PT + OT | Laboratory | Period \(\times\) Group effect |
Howie et al. [11] | 21 DCD (ABBA) | 16Â weeks | VR - CONV vs CONV - VR | Commercially available | No effects |
Preston et al. [12] | 15 CP (AB) | 6 weeks | VR + CONV vs CONV | Laboratory | No effects |
Sakzewski et al. [13] | 58 ABI (AB) | 120 ses | VR vs CONV | Commercially available | No effects |
Bedair et al. [14] | 40 CP (AB) | 96 ses | VR + PT vs CONV | Commercially available | Therapy effects |
Sajan et al. [15] | 20 CP (AB) | 18 ses | VR vs CONV | Commercially available | Therapy effects |
Kassee et al. [16] | 6 CP (AB) | 6 weeks | VR vs PT | Commercially available | No effects |
El Shamy [17] | 30 CP (AB) | 36 ses | VR vs CONV | Laboratory | Therapy effects |
Cavalcante Neto et al. [18] | 32 DCD | 8 ses | VR vs CONV | Commercially available | Therapy effects |
Tarakci et al. [19] | 30 CP + 43 JIA + 19 BPBI (AB) | 24 ses | LMC - VR vs CONV | Commercially available | Period effects |